Italia markets closed

Scinai Immunotherapeutics Ltd. (SCNI)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
3,4900+0,6700 (+23,76%)
Alla chiusura: 04:00PM EDT
3,4000 -0,09 (-2,58%)
Dopo ore: 07:59PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,8200
Aperto2,9000
Denaro3,4000 x 100
Domanda0,0000 x 0
Min-Max giorno2,6700 - 4,3300
Intervallo di 52 settimane2,2300 - 18,7000
Volume1.394.526
Media Volume43.934
Capitalizzazione2,028M
Beta (mensile su 5 anni)2,45
Rapporto PE (ttm)N/D
EPS (ttm)-16,0000
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A700,00
  • GlobeNewswire

    Scinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023

    Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trialsJERUSALEM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) today announced that it will be showcasing its CDMO services at CPHI Barcelona, one of the international pharmaceutical industry’s premier trade shows, taking place October 24 to 26. Several members of Scinai’s executive leadership team will

  • GlobeNewswire

    Scinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offering

    JERUSALEM, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced the closing of its previously announced registered direct offering of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), each ADS

  • GlobeNewswire

    Scinai Immunotherapeutics Announces $1.33 Million Registered Direct Offering

    JERUSALEM, Sept. 15, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announced that it has entered into a definitive agreement for the purchase and sale of 1,146,552 of the Company’s American Depositary Shares (“ADSs”) (or ADS equivalents), ea